Research programme: early research therapeutics - ENYO Pharma/Inserm

Drug Profile

Research programme: early research therapeutics - ENYO Pharma/Inserm

Alternative Names: EBOLACURE; MIMESIS

Latest Information Update: 16 Dec 2016

Price : $50

At a glance

  • Originator ENYO Pharma
  • Developer ENYO Pharma; INSERM
  • Class Anti-infectives; Antineoplastics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Influenza virus infections
  • Research Cancer; Ebola virus infections; Viral infections

Most Recent Events

  • 12 Dec 2016 Early research in Influenza viral infections in France (PO) before December 2016
  • 12 Dec 2016 Preclinical trials in Influenza virus infections in France (IV) before December 2016
  • 06 Dec 2016 Early research in Cancer in France before December 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top